Explore

INTRODUCING CARLOS

A real-world evidence study of effectiveness, adherence and patient experience with every-2-month VOCABRIA + REKAMBYS[1,2]

Explore efficacy from SOLAR

Find out what trial patients think about long-acting treatment

Explore safety and tolerability information

Contact us for support

AE=adverse events, AIDS=acquired immunodeficiency syndrome; ART=antiretroviral therapy;BIC/FTC/TAF=bictegravir/emtricitabine/tenofovir alafenamide; BMI=body mass index; COVID-19=coronavirus disease 2019; CVF=confirmed virologic failure; DTG/3TC=dolutegravir/lamivudine; DTG/3TC/ABC=dolutegravir/ lamivudine/abacavir; HIV=human immunodeficiency virus; HIV-1=human immunodeficiency virus type 1; IQR=interquartile range; ISR=injection site reaction; RNA=ribonucleic acid.

References:

  1. Borch J, Scherzer J, Jonsson-Oldenbüttel C, et al. 6-Month Outcomes of Every 2 Months Long-Acting Cabotegravir and Rilpivirine in a Real-World Setting – Effectiveness, Adherence to Injections, and Patient-Reported Outcomes of People Living With HIV in the German CARLOS Cohort. Presented at: HIV Drug Therapy Glasgow; October 23–26, 2022; Glasgow, UK. Presentation O43.
  2. Scherzer J, Noe S, Jonsson-Oldenbüttel C, et al. Perceptions of Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) From People Living With HIV (PLHIV) in the CARLOS Study. Presented at: The 12th IAS Conference on HIV Science; July 23–26 2023; Brisbane, Australia. Poster EPE0863.
  3. Scherzer J, Noe S, Jonsson-Oldenbüttel C, et al. Perceptions of cabotegravir + rilpivirine long-acting (CAB+RPV LA) from people living with HIV (PLHIV) in the CARLOS Study. Presented at: The 12th IAS Conference on HIV Science; July 23–26 2023; Brisbane, Australia. Abstract EPE0863.
  4. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety and tolerability of switching to long-acting cabotegravir + rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4.
  5. VOCABRIA (cabotegravir) Summary of Product Characteristics (SmPC).
  6. REKAMBYS (rilpivirine) Summary of Product Characteristics (SmPC).

REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.

PM-GB-CBR-WCNT-240010 | October 2024

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.